CDK4/6 inhibitors combined with endocrine therapy are currently the standard of care for the treatment of patients with hormone-receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2−) advanced breast cancer and those with high-risk early disease. The gene discussed is NR4A1; the disease is breast carcinoma.